956 results on '"Branford, Susan"'
Search Results
2. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
3. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib
4. Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
5. Asciminib monotherapy as frontline treatment of chronic phase chronic myeloid leukemia: results from the ASCEND study
6. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition
7. Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication
8. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
9. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
10. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
11. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
12. Response-Related Predictors of Survival and of Treatment-Free Remission in CML
13. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant
14. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
15. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
16. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
17. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
18. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia
19. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
20. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
21. The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
22. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
23. P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES
24. S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
25. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha
26. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
27. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
28. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
29. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis
30. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1tyrosine kinase inhibitors in chronic myeloid leukemia?
31. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
32. CCR Translation for This Article from BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment
33. Supplementary Tables 1-3, Figures 1-2 and Methods from BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment
34. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
35. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
36. Seronegative Rheumatoid Arthritis and Innate Immune Activation is Frequent in Myeloid Neoplasms with Isocitrate Dehydrogenase 1/2 Mutations
37. Monitoring and defining early response: Where to draw the line?
38. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
39. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
40. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
41. Measurable residual disease in chronic myeloid leukemia
42. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
43. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
44. First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
45. Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML
46. Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
47. RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia
48. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
49. Monitoring Disease Response
50. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.